RSV Prevention Strategies in Korean Children: A Review of Current Approaches and Emerging Options.

Abstract

Respiratory syncytial virus (RSV) poses a significant threat to infants and young children in Korea and globally. Current preventive measures, such as palivizumab, have limitations, necessitating the exploration of new strategies. Nirsevimab, a long-acting monoclonal antibody, has emerged as a promising option for protecting all infants from RSV. Clinical trials and real-world evidence support its effectiveness in reducing RSV-related hospitalizations. The economic burden of RSV infection in Korea underscores the need for cost-effective interventions. While several RSV vaccines are under development, none are currently available in Korea. Maternal immunization programs and vaccines for older infants offer potential avenues for expanding protection. This review highlights the evolving landscape of RSV prevention, with a shift towards nirsevimab and future vaccines. Further research is crucial to understand the long-term consequences of RSV infection and develop comprehensive prevention strategies tailored to the Korean population.